Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 5Waldenstrom Macroglobulinemia 3Recurrence 3Lymphoma 2Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Lymphoma, Large B-Cell, Diffuse 1Disease Progression 1

Interventions

eculizumab 3ublituximab 1ravulizumab 1Sugars 1Rituximab 1Plasma Exchange 1OM 89 1N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide 1Mitoxantrone 1LFB-R603 1Interferon beta-1a 1Immunoglobulins, Intravenous 1Adrenal Cortex Hormones 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myelitis, Transverse × ublituximab × Clear all
NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed
6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡